A Potential “Game-Changer” for the Pipeline
Day One CEO Jeremy Bender said the acquisition represents a strategic expansion of the company’s mission to deliver impactful oncology therapies:
“This acquisition will add a potential game-changing new medicine to the Day One portfolio,” Bender said. “If approved, Emi-Le could significantly broaden our opportunities for patient impact, growth, and long-term value.”
He emphasized that Day One’s research, development, and commercial infrastructure is primed to accelerate therapies for rare and life-threatening cancers affecting patients of all ages.
Shareholder Commitments and Delisting Ahead
A separate statement from Mersana confirmed that its executive team, board members, and shareholders affiliated with Bain—together holding about 8.5% of outstanding shares—have agreed to tender their stock.
Once the deal closes—expected by the end of January—Mersana will become a wholly owned Day One subsidiary, and its shares will be removed from public markets.
